JoAnne L. Flynn

JoAnne L. Flynn

Auto-generated profile, based on publicly available information

JoAnne L. Flynn

Department of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Annual Review of Immunology
Verified
Journal Article
Closed access
JFJoAnne L. Flynn
JoAnne L. Flynn
JCJohn Chan
John Chan
The resurgence of tuberculosis worldwide has intensified research efforts directed at examining the host defense and pathogenic mechanisms operative in Mycobacterium tuberculosis infection. This review summarizes our current understanding of the host immune response, with emphasis on the roles of macrophages, T cells, and the cytokine/chemokine network in engendering protective immunity. Specifically, we summarize studies addressing the ability of the organism to survive within macrophages by controlling phagolysosome fusion. The recent studies on Toll-like receptors and the impact on the innate response to M. tuberculosis are discussed. We also focus on the induction, specificity, and effector functions of CD4+and CD8+T cells, and the roles of cytokines and chemokines in the induction and effector functions of the immune response. Presentation of mycobacterial antigens by MHC class I, class II, and CD1 as well as the implications of these molecules sampling various compartments of the cell for presentation to T cells are discussed. Increased attention to this disease and the integration of animal models and human studies have afforded us a greater understanding of tuberculosis and the steps necessary to combat this infection. The pace of this research must be maintained if we are to realize an effective vaccine in the next decades.

15 December 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PLPhilana Ling Lin
Philana Ling Lin
CFChristopher B Ford
Christopher B Ford
MCM Teresa Coleman
M Teresa Coleman
AMAmy J Myers
Amy J Myers
RGRicha Gawande
Richa Gawande
JFJoAnne L Flynn
JoAnne L Flynn
Understanding how Mycobacterium tuberculosis is controlled by the body, leading to active disease in only a small fraction of infected individuals, is important for developing medical interventions to prevent and manage disease. Lin et al. now show that infected macaques with active tuberculosis have some sterile granulomas, suggesting immune-mediated control at certain sites of infection. Insight into the mechanisms underlying the heterogeneity of mycobacterial killing may inform vaccine development. Over 30% of the world's population is infected with Mycobacterium tuberculosis (Mtb), yet only ∼5–10% will develop clinical disease1. Despite considerable effort, researchers understand little about what distinguishes individuals whose infection progresses to active tuberculosis (TB) from those whose infection remains latent for decades. The variable course of disease is recapitulated in cynomolgus macaques infected with Mtb2. Active disease occurs in ∼45% of infected macaques and is defined by clinical, microbiologic and immunologic signs, whereas the remaining infected animals are clinically asymptomatic2,3. Here, we use individually marked Mtb isolates and quantitative measures of culturable and cumulative bacterial burden to show that most lung lesions are probably founded by a single bacterium and reach similar maximum burdens. Despite this observation, the fate of individual lesions varies substantially within the same host. Notably, in active disease, the host sterilizes some lesions even while others progress. Our data suggest that lesional heterogeneity arises, in part, through differential killing of bacteria after the onset of adaptive immunity. Thus, individual lesions follow diverse and overlapping trajectories, suggesting that critical responses occur at a lesional level to ultimately determine the clinical outcome of infection. Defining the local factors that dictate outcome will be useful in developing effective interventions to prevent active TB.

24 July 2017 in Nature Reviews Immunology
Verified
Journal Article
Open access
PDF file
ACAnthony M. Cadena
Anthony M. Cadena
SFSarah M. Fortune
Sarah M. Fortune
JFJoAnne L. Flynn
JoAnne L. Flynn
Tuberculosis (TB) is a highly complex and variable disease that presents along a spectrum of infection outcomes. The TB granuloma is a primary contributor to the biological heterogeneity of TB. Local inflammation, the immune response and bacterial state all contribute to the outcome of a granuloma, and thus there are multiple pathways by which to either achieve control or promote dissemination. The failure of one or a few granulomas is sufficient to initiate disease progression and influence the clinical status of the host.

14 May 2010 in Science
Verified
Journal Article
Closed access
PDF file
DRDavid Russell
David Russell
CIClifton Earl Barry, III
Clifton Earl Barry, III
JFJoAnne L. Flynn
JoAnne L. Flynn
Mycobacterium tuberculosis has a penetrance of its host population that would be the envy of most human pathogens. About one-third of the human population would have a positive skin test for the infection and is thus thought to harbor the bacterium. Globally, 22 “high-burden” countries account for more than 80% of the active tuberculosis cases in the world, which shows the inequitable distribution of the disease. There is no effective vaccine against infection, and current drug therapies are fraught with problems, predominantly because of the protracted nature of the treatment and the increasing occurrence of drug resistance. Here we focus on the biology of the host-pathogen interaction and discuss new and evolving strategies for intervention.

1 October 2003 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
SCSaverio V. Capuano
Saverio V. Capuano
DCDenise A. Croix
Denise A. Croix
SPSantosh Pawar
Santosh Pawar
AZAngelica Zinovik
Angelica Zinovik
AMAmy Myers
Amy Myers
JFJoAnne L. Flynn
JoAnne L. Flynn
Nonhuman primates were used to develop an animal model that closely mimics humanMycobacterium tuberculosisinfection. Cynomolgus macaques were infected with low doses of virulentM. tuberculosisvia bronchoscopic instillation into the lung. All monkeys were successfully infected, based on tuberculin skin test conversion and peripheral immune responses toM. tuberculosisantigens. Progression of infection in the 17 monkeys studied was variable. Active-chronic infection, observed in 50 to 60% of monkeys, was characterized by clear signs of infection or disease on serial thoracic radiographs and in other tests and was typified by eventual progression to advanced disease. Approximately 40% of monkeys did not progress to disease in the 15 to 20 months of study, although they were clearly infected initially. These monkeys had clinical characteristics of latent tuberculosis in humans. Low-dose infection of cynomolgus macaques appears to represent the full spectrum of humanM. tuberculosisinfection and will be an excellent model for the study of pathogenesis and immunology of this infection. In addition, this model will provide an opportunity to study the latentM. tuberculosisinfection observed in ∼90% of all infected humans.

1 October 2009 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
PLPhilana Ling Lin
Philana Ling Lin
MRMark Rodgers
Mark Rodgers
LSLe'Kneitah Smith
Le'Kneitah Smith
MBMatthew Bigbee
Matthew Bigbee
AMAmy Myers
Amy Myers
JFJoAnne L. Flynn
JoAnne L. Flynn
We previously described that low-dose Mycobacterium tuberculosis infection in cynomolgus macaques results in a spectrum of disease similar to that of human infection: primary disease, latent infection, and reactivation tuberculosis (S. V. Capuano III, D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin, S. Bissel, C. Fuhrman, E. Klein, and J. L. Flynn, Infect. Immun. 71: 5831-5844, 2003). This is the only established model of latent infection, and it provides a unique opportunity to understand host and pathogen differences across of range of disease states. Here, we provide a more extensive and detailed characterization of the gross pathology, microscopic histopathology, and immunologic characteristics of monkeys in each clinical disease category. The data underscore the similarities between human and nonhuman primate M. tuberculosis infection. Furthermore, we describe novel methods of quantifying gross pathology and bacterial burden that distinguish between active disease and latent infection, and we extend the usefulness of this model for comparative studies. Early in infection, an abnormal chest X ray, M. tuberculosis growth by gastric aspirate, and increased mycobacterium-specific gamma interferon (IFN-γ) in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage (BAL) cells were associated with the development of active disease. At necropsy, disease was quantified with respect to pathology and bacterial numbers. Microscopically, a spectrum of granuloma types are seen and differ with disease type. At necropsy, monkeys with active disease had more lung T cells and more IFN-γ from PBMC, BAL, and mediastinal lymph nodes than monkeys with latent infection. Finally, we have observed a spectrum of disease not only in monkeys with active disease but also in those with latent infection that provides insight into human latent tuberculosis.